Pulse Biosciences (PLSE) Projected to Post Earnings on Tuesday

Key Points

• Pulse Biosciences will release its Q2 2025 earnings results on Tuesday, August 12th, with analysts expecting a loss of ($0.26) per share.
• The company's stock price increased by 1.7% to $15.33, although it trades below its 200-day moving average of $17.12.
• Oppenheimer has initiated coverage on Pulse Biosciences, giving it an "outperform" rating and a price target of $22.00.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) is anticipated to announce its Q2 2025 earnings results after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.25) EPS for the quarter.

Pulse Biosciences Trading Down 0.1%

Pulse Biosciences stock traded down $0.01 during trading hours on Friday, hitting $14.71. The stock had a trading volume of 101,099 shares, compared to its average volume of 140,769. The company has a 50-day moving average of $15.57 and a two-hundred day moving average of $17.03. Pulse Biosciences has a fifty-two week low of $13.77 and a fifty-two week high of $25.00.

Insider Buying and Selling at Pulse Biosciences

In other news, CTO Darrin Uecker sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $16.40, for a total value of $246,000.00. Following the sale, the chief technology officer directly owned 137,872 shares in the company, valued at approximately $2,261,100.80. This represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 71.50% of the company's stock.

Institutional Investors Weigh In On Pulse Biosciences

A hedge fund recently bought a new stake in Pulse Biosciences stock. Jane Street Group LLC acquired a new stake in Pulse Biosciences, Inc (NASDAQ:PLSE - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 20,105 shares of the company's stock, valued at approximately $323,000. Institutional investors own 76.95% of the company's stock.

Analyst Ratings Changes

Separately, Oppenheimer started coverage on Pulse Biosciences in a report on Monday, July 7th. They issued an "outperform" rating and a $22.00 price target for the company.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.